Erste Asset Management GmbH Purchases New Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Erste Asset Management GmbH acquired a new position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund acquired 51,200 shares of the company’s stock, valued at approximately $725,000. Erste Asset Management GmbH owned about 0.05% of Day One Biopharmaceuticals as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in DAWN. SG Americas Securities LLC bought a new stake in shares of Day One Biopharmaceuticals in the second quarter worth $113,000. SteelPeak Wealth LLC bought a new stake in shares of Day One Biopharmaceuticals in the 2nd quarter worth about $218,000. Hennion & Walsh Asset Management Inc. lifted its position in shares of Day One Biopharmaceuticals by 8.6% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 64,359 shares of the company’s stock worth $887,000 after purchasing an additional 5,070 shares during the last quarter. Renaissance Technologies LLC acquired a new position in Day One Biopharmaceuticals in the second quarter worth about $994,000. Finally, Hsbc Holdings PLC bought a new stake in Day One Biopharmaceuticals in the second quarter valued at about $163,000. 87.95% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 30,000 shares of the business’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $14.22, for a total transaction of $426,600.00. Following the sale, the insider now directly owns 1,097,535 shares in the company, valued at approximately $15,606,947.70. The trade was a 2.66 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 51,745 shares of company stock valued at $775,867 in the last quarter. Corporate insiders own 8.40% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Needham & Company LLC reaffirmed a “buy” rating and set a $33.00 target price on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st. HC Wainwright restated a “buy” rating and set a $40.00 price objective on shares of Day One Biopharmaceuticals in a research note on Thursday, October 31st. TD Cowen upgraded shares of Day One Biopharmaceuticals to a “strong-buy” rating in a research note on Monday, November 4th. Finally, JPMorgan Chase & Co. reduced their price target on shares of Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 6th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Day One Biopharmaceuticals has an average rating of “Buy” and an average price target of $35.71.

Day One Biopharmaceuticals Stock Performance

Day One Biopharmaceuticals stock opened at $13.59 on Wednesday. The company has a 50-day simple moving average of $14.31 and a 200-day simple moving average of $14.11. Day One Biopharmaceuticals, Inc. has a one year low of $11.51 and a one year high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings results on Wednesday, October 30th. The company reported $0.38 EPS for the quarter, beating the consensus estimate of ($0.20) by $0.58. The firm had revenue of $93.76 million during the quarter, compared to analyst estimates of $15.05 million. During the same quarter in the previous year, the business posted ($0.54) EPS. On average, research analysts predict that Day One Biopharmaceuticals, Inc. will post -0.88 earnings per share for the current fiscal year.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.